Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

ClinicalTrials.gov ID: NCT03513952

Public ClinicalTrials.gov record NCT03513952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Study identification

NCT ID: NCT03513952
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 47 participants

Conditions and interventions

Conditions

Interventions

Atezolizumab Drug
Biopsy Procedure
Biospecimen Collection Procedure
Computed Tomography Procedure
Glycosylated Recombinant Human Interleukin-7 Biological
Laboratory Biomarker Analysis Other
Magnetic Resonance Imaging Procedure
Positron Emission Tomography and Computed Tomography Scan Procedure

Drug · Procedure · Biological + 1 more

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2019
Primary completion: Sep 29, 2023
Completion: Mar 31, 2024
Last update posted: Jul 25, 2024

2019 – 2024

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Kaiser Permanente-Riverside	Riverside	California	92505	—
Moffitt Cancer Center	Tampa	Florida	33612	—
Straub Clinic and Hospital	Honolulu	Hawaii	96813	—
University of Hawaii Cancer Center	Honolulu	Hawaii	96813	—
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
East Jefferson General Hospital	Metairie	Louisiana	70006	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
FHCC South Lake Union	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03513952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2024 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03513952 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →